Group 1 - Health 160 (02656.HK) saw its stock price increase by over 8% during trading, reaching a new high of 42.34 HKD [2] - The stock has risen more than 256% compared to its initial offering price of 11.89 HKD [2]

Core Viewpoint - Health 160 (02656) has seen a significant increase in stock price, rising over 256% from its IPO price of HKD 11.89 to a peak of HKD 42.34, indicating strong market interest and confidence in the company's business model and growth potential [1] Company Overview - Health 160 is an experienced wholesale distributor of pharmaceutical and health products in China, as well as a leading provider of integrated digital healthcare services [1] - The company offers a wide range of pharmaceutical health products and comprehensive digital healthcare solutions [1] Digital Healthcare Platform - Health 160 operates an online healthcare service platform that connects various stakeholders in the healthcare industry, enhancing the overall healthcare ecosystem [1] - As of March 31, 2025, the platform has connected over 44,600 healthcare institutions, including more than 14,400 hospitals (of which 3,430 are tertiary hospitals) and over 30,200 grassroots healthcare institutions [1] - Among the partnered healthcare institutions, over 6,800 private entities provide consumer medical services such as dental, ophthalmology, and health check-up services through the platform [1]

Core Viewpoint - Health 160 (02656) has seen a significant stock price increase, rising over 256% from its IPO price of 11.89 HKD to a peak of 42.34 HKD, indicating strong market interest and confidence in the company's business model and growth potential [1] Company Overview - Health 160 is an experienced Chinese pharmaceutical and health products wholesaler and a leading provider of digital healthcare integrated services [1] - The company offers a wide range of pharmaceutical health products and comprehensive digital healthcare solutions [1] Digital Healthcare Platform - Health 160 operates an online healthcare service platform that provides digital healthcare solutions, empowering various participants in the healthcare industry [1] - As of March 31, 2025, the platform has connected over 44,600 healthcare institutions, including more than 14,400 hospitals (of which 3,430 are tertiary hospitals) and over 30,200 grassroots healthcare institutions [1] - Among the partnered healthcare institutions, over 6,800 private entities primarily offer consumer medical services such as dental, ophthalmology, and health check-up services through the platform [1]

Core Viewpoint - Health 160 (02656) has seen a significant increase in stock price, rising over 230% from its IPO price of 11.89 HKD to a peak of 39.5 HKD, indicating strong market interest and performance [1] Company Overview - Health 160 is an experienced wholesaler of pharmaceutical and health products in China, as well as a leading provider of integrated digital healthcare services [1] - The company offers a wide range of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform, connecting various stakeholders in the healthcare industry [1] Platform Connectivity - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions since its inception [1]

Core Viewpoint - Health 160 (02656) has seen a significant increase in stock price, rising over 230% from its IPO price of 11.89 HKD to a peak of 39.5 HKD, indicating strong market interest and performance [1] Company Overview - Health 160 is an experienced wholesale distributor of pharmaceutical and health products in China, as well as a leading provider of integrated digital healthcare services [1] - The company offers a wide range of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform, connecting various stakeholders in the healthcare industry [1] Platform Connectivity - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions since its inception [1]

Core Viewpoint - The stock of Health 160 (02656.HK) in Hong Kong surged over 10% towards the end of trading on October 3, reaching a price of 34.92 HKD with a trading volume of 35.79 million HKD [1] Summary by Category - **Stock Performance** - Health 160's stock increased by 10.16% [1] - The closing price was reported at 34.92 HKD [1] - The total trading volume amounted to 35.79 million HKD [1]

Core Viewpoint - Health 160 (02656) has seen a significant stock price increase, rising over 10% to reach a new high of 35 HKD, nearly doubling from its IPO price of 11.89 HKD [1] Company Overview - Health 160 is an experienced Chinese pharmaceutical and health products wholesaler and a leading provider of digital healthcare integrated services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform, connecting various stakeholders in the healthcare industry [1] Platform Connectivity - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions since its inception [1] - This includes more than 14,400 hospitals, of which 3,430 are tertiary hospitals, and over 30,200 grassroots healthcare institutions [1]

備註： 公司名稱: 健康160国际有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02656 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30 ...

Healthcare Network and User Base - As of June 30, 2025, the platform has connected over 44,800 healthcare institutions, including more than 14,500 hospitals and over 30,300 grassroots healthcare institutions[10]. - The registered individual users on the platform reached 56.9 million, with an average of 3.3 million monthly active users in the six months ending June 30, 2025[10]. - The company collaborates with over 904,500 healthcare professionals, including approximately 46,700 registered doctors, to enrich its medical resources[10]. - The company has developed a digital healthcare service platform that integrates online and offline healthcare services, significantly expanding its service reach to over 260 cities nationwide[10]. - The company has established 11 regional operation centers in key areas such as Shenzhen, Beijing, Shanghai, and Guangzhou to enhance local service coverage[11]. Financial Performance - Total revenue for the six months ended June 30, 2025, was RMB 290.7 million, representing a year-on-year increase of 6.2%[16]. - Revenue from pharmaceutical health products sales reached RMB 211.4 million, up 7.4% year-on-year[19]. - The company reported an operating loss of RMB 18.0 million, a significant improvement of 77.8% compared to the previous year's loss of RMB 81.2 million[16]. - The adjusted net loss (non-IFRS measure) was RMB 5.1 million, a reduction of 83.7% from RMB 31.0 million in the prior year[16]. - Revenue from digital healthcare solutions was RMB 79.3 million, reflecting a year-on-year growth of 2.9%[20]. Cost Management and Expenses - Sales and marketing expenses decreased by 45.5% from approximately RMB 64.9 million to approximately RMB 35.4 million, primarily due to reduced employee benefits expenses and improved cost control measures[32]. - Administrative expenses fell by 46.5% from approximately RMB 51.5 million to approximately RMB 27.5 million, mainly due to a reduction in share-based payment expenses and travel costs[33]. - Research and development expenses decreased by 30.5% from approximately RMB 25.1 million to approximately RMB 17.5 million, reflecting a reduction in employee benefits expenses[35]. - The gross margin for pharmaceutical health products sales decreased from 1.9% to 1.3%, while the retail model's gross margin increased from 13.1% to 16.2% due to strategic adjustments in product selection and promotional activities[31]. Cash Flow and Liquidity - The operating cash flow for the six months ended June 30, 2025, was a net outflow of RMB 5.4 million, an improvement from a net outflow of RMB 40.7 million in the same period of 2024[44]. - The company reported a net cash inflow from financing activities of RMB 12.3 million for the six months ended June 30, 2025, compared to RMB 36.7 million in the same period of 2024[44]. - As of June 30, 2025, the company's cash and cash equivalents amounted to approximately RMB 66.8 million, an increase from RMB 58.3 million as of December 31, 2024[43]. - The company’s total liabilities exceeded current assets by RMB 107,091,000 as of June 30, 2025, highlighting potential liquidity challenges[111]. Shareholder and Equity Information - The total number of issued shares is 336,452,810[68]. - Major shareholders include Mr. Luo, holding approximately 30.59% of the company's shares[73]. - The company approved a pre-IPO share option plan on August 31, 2023, aimed at attracting and retaining senior management and employees[79]. - A total of 14,487,990 new shares and 16,696,595 existing shares can be issued under the pre-IPO share option plan, representing 4.31% and 4.96% of the total issued shares post-split and global offering, respectively[81]. - The company aims to align the interests of option holders with those of shareholders through the share option plan[79]. Future Plans and Investments - The company plans to adopt new accounting standards effective January 1, 2026, but does not expect significant impacts on its financial position or performance[113]. - The company plans to list its shares on the Hong Kong Stock Exchange on September 17, 2025[162]. - The company has no specific future plans for significant investments or capital assets as of June 30, 2025[50]. - The company continues to expand its market presence and promote its digital hospital solutions to enhance service levels and reach more regions[18]. Guarantees and Related Party Transactions - The company provided a revolving credit loan of RMB 60 million to its controlling shareholder, Mr. Luo, with an interest rate between 3.45% and 6%[151]. - The company has guaranteed loans totaling RMB 28,000,000 as of June 30, 2025, with various related parties providing collateral[152]. - The company has a loan guarantee of RMB 5,000,000 from Bank H, guaranteed by Mr. Luo, with a start date of January 13, 2025, and an end date of January 12, 2026[154].

Core Viewpoint - Health 160 (02656) announced the appointment of Ms. Sun Meng as a non-executive director and Mr. Zou Jun as an independent non-executive director to the nomination committee of the board, effective from September 29, 2025 [1] Group 1 - Ms. Sun Meng has been appointed as a member of the nomination committee [1] - Mr. Zou Jun has also been appointed as a member of the nomination committee [1] - The appointments will take effect on September 29, 2025 [1]